DYNE THERAPEUTICS, INC.
DYNLoading price...
Overview
Previous Close24.28
Open17.08
Ask20.47
Bid17.35
Day's Range17 - 20.9
52 Week Range11.92 - 27.31
PE Ratio(TTM)--
Market Cap3,79,28,19,968
Volume1,70,66,619
Avg. Volume22,38,355
Analyst Consensus
Rating Breakdown (17 analysts)
Strong Buy: 3Buy: 13Hold: 0Sell: 0Strong Sell: 1
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | ||||||
|---|---|---|---|---|---|---|
| No results to display | ||||||
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Waltham, United States
Website: https://www.dyne-tx.com
CEO, President & Director: Mr. John G. Cox M.B.A.
Employees: 289
About Company:
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.